Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Coeptis Therapeutics logo — A biopharmaceutical company developing innovative cell thera...

Coeptis Therapeutics

A biopharmaceutical company developing innovative cell therapy platforms for patients with cancer (NASDAQ: COEP)

Founded 1996 7 employees Post Ipo Equity Total: $15.32M Biotechnology, Health Care +1

General Information

Company Name Coeptis Therapeutics
Founded Year 1996
Employees 7
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Coeptis Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Coeptis Therapeutics

Coeptis Therapeutics (NASDAQ: COEP) is a biopharmaceutical company founded in 1996, dedicated to developing innovative cell therapy platforms for patients battling cancer. Specializing in the Biotechnology, Health Care, and Pharmaceutical industries, Coeptis Therapeutics has recently secured a significant $4.30M Post-IPO Equity investment from CJC on 20 June 2024. This funding rounds not only reflects the market's confidence in Coeptis Therapeutics's vision and potential but also positions the company for further advancements in its groundbreaking research and development efforts. With its firm focus on addressing unmet needs in cancer treatment, Coeptis Therapeutics remains a key player in driving innovation within the biopharmaceutical space.

Taxonomy: biopharmaceutical, cell therapy, cancer treatment, pharmaceutical development, innovation, partnerships, product pipeline, acquisition, pharmaceutical company, oncology, NASDAQ, therapy platforms, drug development, clinical trials

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 1 •••• •••• 20 Jun 2024
Post-IPO Equity •••••• - 24 Oct 2023
Post-IPO Equity •••••• - 14 Jun 2023
Venture Round •••••• - 27 Jul 2021

Coeptis Therapeutics Alternatives & Competitors

Coeptis Therapeutics vs
Citron Pharma
Citron Pharma

A privately held pharmaceutical company dedicated to creating and promoting generic products across...

Biotechnology, Health Care
Coeptis Therapeutics vs
Pikralida
Pikralida Poland

Pikralida - A drug development company

Unknown
20 employees
Coeptis Therapeutics vs
Mendability
Mendability United States

The power of Sensory Enrichment Therapy to help the brain

10 employees
Health Care

FAQ About Coeptis Therapeutics

A biopharmaceutical company developing innovative cell therapy platforms for patients with cancer (NASDAQ: COEP)
Coeptis Therapeutics was founded in 1996.
Coeptis Therapeutics operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Coeptis Therapeutics has approximately 7 employees.
Coeptis Therapeutics has completed 4 funding rounds, raising a total of $15.32M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Coeptis Therapeutics include Citron Pharma, Pikralida, Mendability, OncoZenge AB, Hybrigenics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Coeptis Therapeutics and Citron Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Coeptis Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy